Nexben 100 mg Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Nexben 100 mg Injection contains bendamustine, an alkylating cytotoxic (chemotherapy) medicine. Its labelling describes it for the treatment of certain cancer types — chronic lymphocytic leukemia (a cancer of the blood and bone marrow), non-Hodgkin’s lymphomas (formed in the lymph system, part of the immune system), and multiple myeloma (a cancer of plasma cells). It is described as killing cancer cells by disrupting the cell cycle and causing DNA damage. It is usually given as an infusion over 30 to 60 minutes and may be given once every three to four weeks, as determined by the doctor.
Product Information
The following description reflects information associated with bendamustine and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of chronic lymphocytic leukemia
- Described for the treatment of non-Hodgkin’s lymphomas
- Described for the treatment of multiple myeloma
- Described as forming covalent bonds with DNA, stopping DNA repair enzymes, and blocking progress of the cell cycle
Described Dosage & Administration
- Given only by a healthcare professional in a hospital setting, into a vein of the arm or hand
- Usually given over 30 to 60 minutes; may be given once every three to four weeks
- The doctor sets the dose, duration, and intervals; treatment may not start if the white blood cell (leukocyte) count is low and below the required level
- The doctor should be told immediately if a dose is missed
Described Side Effects
Commonly described side effects include:
- Infection and fever
- Low blood cell count
- Headache and dizziness
- Nausea and loss of appetite
- Insomnia and fatigue
- Hair loss
- Itching and rash
- Constipation and dehydration
- Missed periods
- Low or high blood pressure
These are described as commonly temporary. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Medical details, including herbal medicines and supplements, should be shared with the healthcare team to avoid wrong medicine mix-ups
- The treatment should be discussed with the doctor by anyone planning a pregnancy with their partner, as this medicine can reduce sperm production in men
- Vials should be stored refrigerated between 2°C and 8°C and not allowed to freeze
- Keep away from children and pets
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains bendamustine and is used for chronic lymphocytic leukemia, non-Hodgkin’s lymphomas, and multiple myeloma. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as given only by a healthcare professional in a hospital setting, into a vein of the arm or hand, usually over 30 to 60 minutes and often once every three to four weeks.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.